New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 18, 2012
19:11 EDTMNOVMedicNova extends MN-166 patent position in Europe
MediciNova announced that it has received Notices of Allowance from the European Patent Office, EPO, for two pending patent applications. One covers the use of ibudilast, MN-166, in drug addiction and the other provides for ibudilast use to enhance opioid analgesia in acute pain settings. MN-166 is the company's lead drug development candidate for certain neurological conditions, including progressive multiple sclerosis, drug addiction, and pain.
News For MNOV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2015
13:47 EDTMNOVMediciNova reports positive interim data from clinical trial of MN-166 in ALS
Subscribe for More Information
April 16, 2015
09:18 EDTMNOVOn The Fly: Pre-market Movers
Subscribe for More Information
08:12 EDTMNOVMediciNova MN-001 granted fast track designation by FDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use